Mediator of RNA polymerase II transcription subunit 30 (MED30)

Mediator of RNA polymerase II transcription subunit 30 (MED30) is a metazoan-specific protein that forms an integral part of the Mediator complex, a central coactivator required for regulated transcription of most RNA polymerase II-dependent genes[2][3][4]. MED30 is structurally localized to the proximal Tail module, anchoring the Head and Tail modules and thereby supporting the stability of the entire Mediator core. It acts as a bridge that recruits and coordinates gene-specific regulatory factors with the transcriptional machinery, facilitating the formation of pre-initiation complexes and modulating gene expression in diverse pathways. MED30 is essential for embryonic and adult heart development; its loss results in destabilization of the Mediator complex, defective cardiac gene expression, suppressed proliferation in embryonic cardiomyocytes, increased apoptosis in adult cardiac cells, and severe or lethal cardiac defects. Mutations in MED30 have been linked to congenital syndromes affecting heart development, including Langer-Giedion syndrome Type II and Cornelia de Lange syndrome 4, as well as mitochondrial cardiomyopathy[1][3]. There are no known approved drugs or clinical targeting strategies for MED30.

Other names

Thyroid hormone receptor-associated protein 6TRAP25THRAP6Mediator complex subunit 30TRAP/Mediator complex component TRAP25Mediator of RNA polymerase II transcription subunit 30MED30SThyroid hormone receptor-associated protein complex 25 kDa componentputative mediator of RNA polymerase II transcription subunit 30